Bayer AG

BAYN

DE000BAY0017

Pharmaceuticals

Real-time Estimate Tradegate Other stock markets 04:21:22 2024-07-08 am EDT			5-day change	1st Jan Change
26.09 ^EUR	-0.29%		-0.17%	-22.32%

08:14am	BAYER AG : Goldman Sachs reiterates its Neutral rating	ZD
Jul. 02	Cartesian Therapeutics, Inc. Appoints Kemal Malik to its Board of Directors	CI

BAYER AG : Goldman Sachs reiterates its Neutral rating

July 08, 2024 at 02:14 am EDT

James Quigley from Goldman Sachs retains his Neutral opinion on the stock. The target price is revised downwards from EUR 31 to EUR 30.

Latest news about Bayer AG

BAYER AG : Goldman Sachs reiterates its Neutral rating	02:14am	ZD
Cartesian Therapeutics, Inc. Appoints Kemal Malik to its Board of Directors	Jul. 02	CI
Borse Frankfurt-News: Uncertainty ahead of French election (Bond Trading)	Jun. 28	DP
Chemicals collective agreement: Bonus days for union members	Jun. 27	DP
German chemical sector employers, union agree 6.85% pay hike over 20 months	Jun. 27	RE
Chemicals collective bargaining agreement: extra day for trade unionists	Jun. 27	DP
The same old winners	Jun. 27
Bayer's pharmaceuticals division plans to cut further managerial jobs	Jun. 27	RE
Bayer's Pharmaceuticals Unit to Cut More Managerial Jobs Amid Reorganization	Jun. 27	MT
Bayer's pharmaceutical unit plans more managerial cuts in Europe, Asia	Jun. 26	RE
Global markets live: Bayer, FedEx, Nvidia, KKR, Verizon...	Jun. 26
Dpa-AFX Overview: COMPANIES from 26.06.2024 - 15:15	Jun. 26	DP
Anton switch to Dortmund perfect? Voller rows back	Jun. 26	DP
Bayer CEO - Making faster progress with restructuring	Jun. 26	RE
Chemical industry wage partners seek solution before the end of the peace period	Jun. 25	DP
Bayer: patients recruited for phase 2 Parkinson's trial	Jun. 25	CF
Bayer and Solynta Collaborate to Advance True Potato Seed in Smallholder Markets	Jun. 23	CI
Global markets live: Vodafone, Bayer, Apple, Microsoft, Qualcomm...	Jun. 19
Bayer's Crop Science Business Developing AI to Kill Weeds	Jun. 19	MT
Bayer looks to AI to combat herbicide resistance faster	Jun. 18	RE
Transcript : Bayer Aktiengesellschaft - Special Call	Jun. 18
New Bayer short corn variety stands up to high winds, but not over 100 mph	Jun. 18	RE
South Africa finds high prices, lack of competition in its fresh produce market	Jun. 18	RE
Economics Minister Habeck travels to China without prominent company representatives	Jun. 18	RE
Alvotech Enters Commercialization Deal for Eylea Biosimilars with Advanz Pharma	Jun. 18	MT

Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (48.8%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (38%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.7%); - other (0.5%). Net sales are distributed geographically as follows: Germany (5.1%), Switzerland (1.2%), Europe-Middle East-Africa (23.2%), the United States (30.6%), North America (3.5%), China (7.6%), Asia-Pacific (10%), Brazil (10.4%) and Latin America (8.4%).

Sector

Pharmaceuticals

Calendar

2024-08-06 - Q2 2024 Earnings Release

Related indices

Euro STOXX 50 Index , STOXX EUROPE 600 (EUR) , DAX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

BAYER : As soft as anticipated

May 14, 2024 at 02:12 pm EDT

Bayer AG: Not out of the woods yet

March 06, 2024 at 10:46 am EST

More Strategies

Ratings for Bayer AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

26.16 EUR

Average target price

36.18 EUR

Spread / Average Target

+38.28%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BAYER AG	-22.32%	27.83B
ELI LILLY AND COMPANY	+56.89%	823B
NOVO NORDISK A/S	+40.60%	627B
JOHNSON & JOHNSON	-6.55%	353B
MERCK & CO., INC.	+15.99%	320B
ABBVIE INC.	+7.92%	295B
ASTRAZENECA PLC	+13.92%	239B
NOVARTIS AG	+13.70%	220B
ROCHE HOLDING AG	-0.57%	219B
AMGEN INC.	+7.94%	167B

Other Pharmaceuticals

Bayer AG

Equities

BAYN

DE000BAY0017

Pharmaceuticals

BAYER AG : Goldman Sachs reiterates its Neutral rating

Latest news about Bayer AG

Chart Bayer AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Bayer AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals